WO1994020139A1 - Utilisation d'anticorps anti-tnf comme medicament therapeutique de l'insuffisance cardiaque (faiblesse du muscle cardiaque) - Google Patents

Utilisation d'anticorps anti-tnf comme medicament therapeutique de l'insuffisance cardiaque (faiblesse du muscle cardiaque) Download PDF

Info

Publication number
WO1994020139A1
WO1994020139A1 PCT/EP1994/000628 EP9400628W WO9420139A1 WO 1994020139 A1 WO1994020139 A1 WO 1994020139A1 EP 9400628 W EP9400628 W EP 9400628W WO 9420139 A1 WO9420139 A1 WO 9420139A1
Authority
WO
WIPO (PCT)
Prior art keywords
heart
tnf antibodies
weakness
therapy
tnf
Prior art date
Application number
PCT/EP1994/000628
Other languages
German (de)
English (en)
Inventor
Karl Werdan
Peter Boekstegers
Joachim Kempeni
Martin Kaul
Original Assignee
Knoll Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Aktiengesellschaft filed Critical Knoll Aktiengesellschaft
Publication of WO1994020139A1 publication Critical patent/WO1994020139A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to the use of anti-TNF antibodies in the treatment of heart failure (heart muscle weakness).
  • tumor necrosis factor encompasses two cytotoxic factors (TNF- ⁇ and TNF- ⁇ ), which are largely formed by activated lymphocytes and monocytes.
  • anti-TNF antibodies are described which are used for diseases such as septic shock, transplant rejection, allergies, autoimmune diseases, shock lung, blood clotting disorders or inflammatory bone diseases which are associated with an increase in TNF in the blood Deactivation of TNF can be used.
  • EP 453 898 teaches the use of anti-TNF antibodies for the treatment of ischemia and the associated symptoms.
  • Heart failure is a clinical syndrome that is characterized not only by cardiac symptoms, but also by functional disorders of the periphery of the organ (see Sturm et al, Basic Terms of Internal Medicine, 13th edition, pp. 67-75, Gustav Fischer Verlag, Stuttgart 1984). . It is not possible to adapt the cardiac output to the requirements of the organism sufficiently (see W. Siegenthaler et al., Textbook of Internal Medicine, 2nd edition, pp. 2 - 11, Georg Thieme Verlag, Stuttgart, 1987). In the case of acute life-threatening heart failure, the cardiac output does not suffice to satisfy the organism's need for rest.
  • anti-TNF antibodies suitable for use according to the invention are known (EP 260 610, EP 351 789, EP 218 868). Both polyclonal and monoclonal antibodies can be used the. TNF-binding antibody fragments such as Fab or F (ab ') 2 fragments and Fv or single-chain Fv fragments are also suitable. Furthermore, humanized or human anti-TNF antibodies or their TNF-binding fragments are also very suitable.
  • the present invention includes pharmaceutical preparations which, in addition to non-toxic, inert pharmaceutically suitable excipients, contain the anti-TNF antibodies and processes for the preparation of these preparations.
  • the anti-TNF antibodies are formulated in a manner customary for active substances produced in bio-technology, as a rule as a liquid formulation or lyophilisate (see, for example, Hager's Handbook of Pharmaceutical Practice, Vol. 2, 5th Edition, 1991, p. 720 , ISBN 3-540-52459-2).
  • the pharmaceutical preparations listed above can also contain other active pharmaceutical ingredients, in particular those known for the treatment of heart failure, such as catecholamines, digitalis, diuretics and vasodilators (e.g. ACE inhibitors).
  • active pharmaceutical ingredients in particular those known for the treatment of heart failure, such as catecholamines, digitalis, diuretics and vasodilators (e.g. ACE inhibitors).
  • the pharmaceutical preparations listed above are prepared in a conventional manner by known methods, e.g. by mixing the active ingredient (s) with the excipient or excipients.
  • the active ingredient (s) suitable for the use according to the invention in total amounts of about 0.1 to about 1000, preferably 0.1 to 10 mg / kg body weight per 24 hours, optionally in the form of several units administered individually or as a continuous infusion and possibly over a therapy period of several days to achieve the desired results.
  • the application can take place as an intravenous short infusion of the individual doses or as a continuous long-term infusion of the daily dose over 24 hours.
  • a single dose contains the active ingredient (s) preferably in amounts of about 0.1 to about 10 mg / kg body weight.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

On utilise, selon l'invention, des anticorps anti-TNF (TNF = tumor necrosis factor = facteur de nécrose des tumeurs) dans le traitement de l'insuffisance cardiaque (faiblesse du muscle cardiaque).
PCT/EP1994/000628 1993-03-10 1994-03-03 Utilisation d'anticorps anti-tnf comme medicament therapeutique de l'insuffisance cardiaque (faiblesse du muscle cardiaque) WO1994020139A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4307508.8 1993-03-10
DE19934307508 DE4307508A1 (de) 1993-03-10 1993-03-10 Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)

Publications (1)

Publication Number Publication Date
WO1994020139A1 true WO1994020139A1 (fr) 1994-09-15

Family

ID=6482398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/000628 WO1994020139A1 (fr) 1993-03-10 1994-03-03 Utilisation d'anticorps anti-tnf comme medicament therapeutique de l'insuffisance cardiaque (faiblesse du muscle cardiaque)

Country Status (2)

Country Link
DE (1) DE4307508A1 (fr)
WO (1) WO1994020139A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016286A2 (fr) 2002-08-16 2004-02-26 Abbott Biotechnology Ltd. Formulation d'anti-corps humains pour le traitement de troubles lies au facteur de necrose tumorale alpha
WO2005110452A2 (fr) 2004-04-09 2005-11-24 Abbott Biotechnology Ltd. Regime posologique a variables multiples destine a traiter des troubles associes a tnf?
EP2196218A2 (fr) 2002-04-26 2010-06-16 Abbott Biotechnology Ltd Utilisation d'anticorps anti-TNFalpha et d'un autre médicament
EP2295071A1 (fr) 2002-10-24 2011-03-16 Abbott Biotechnology Ltd Thérapies faiblement dosées pour traiter des troubles pour lesquels l'activité des facteurs de nécrose tumorale alpha est préjudiciable
EP2305713A1 (fr) 1996-02-09 2011-04-06 Abbott Biotechnology Ltd Anticorps humains se fixant au facteur nécrosant des tumeurs de type alpha
EP2324851A1 (fr) 2001-06-08 2011-05-25 Abbott Biotechnology Ltd Methodes d'administration d'anticorps anti-TNFalpha
EP2738178A1 (fr) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Purification d'anticorps
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
US9365645B1 (en) 2011-04-27 2016-06-14 Abbvie, Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2016160976A2 (fr) 2015-03-30 2016-10-06 Abbvie Inc. Protéines de liaison au tnf monovalentes
EP3078676A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9499616B2 (en) 2013-10-18 2016-11-22 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9522953B2 (en) 2013-10-18 2016-12-20 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9683033B2 (en) 2012-04-20 2017-06-20 Abbvie, Inc. Cell culture methods to reduce acidic species
US9688752B2 (en) 2013-10-18 2017-06-27 Abbvie Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9708400B2 (en) 2012-04-20 2017-07-18 Abbvie, Inc. Methods to modulate lysine variant distribution
US9708399B2 (en) 2013-03-14 2017-07-18 Abbvie, Inc. Protein purification using displacement chromatography
WO2018124948A1 (fr) 2016-12-30 2018-07-05 Закрытое Акционерное Общество "Биокад" Composition pharmaceutique aqueuse d'un anticorps monoclonal recombinant pour le facteur de nécrose tumorale (tnf) α

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008460A1 (fr) * 1988-03-11 1989-09-21 Celltech Limited Anticorps utilises dans le traitement faisant intervenir des anticorps anti-lymphocytes
EP0453898A2 (fr) * 1990-04-25 1991-10-30 Bayer Ag Utilisation d'anticorps contre le facteur de nécrose tumorale (TNF) comme médicament pour le traitement d'ischémies et de leurs conséquences
WO1992011383A1 (fr) * 1990-12-21 1992-07-09 Celltech Limited ANTICORPS DE RECOMBINAISON SPECIFIQUE AU FNT-$g(a)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008460A1 (fr) * 1988-03-11 1989-09-21 Celltech Limited Anticorps utilises dans le traitement faisant intervenir des anticorps anti-lymphocytes
EP0453898A2 (fr) * 1990-04-25 1991-10-30 Bayer Ag Utilisation d'anticorps contre le facteur de nécrose tumorale (TNF) comme médicament pour le traitement d'ischémies et de leurs conséquences
WO1992011383A1 (fr) * 1990-12-21 1992-07-09 Celltech Limited ANTICORPS DE RECOMBINAISON SPECIFIQUE AU FNT-$g(a)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 116, no. 21, 25 May 1992, Columbus, Ohio, US; abstract no. 212586j, S.C. SMITH ET AL.: "NEUTRALIZATION OF ENDOGENOUS TUMOR NECROSIS FACTOR AMELIORATES THE SEVERITY OF MYOSIN-INDUCED MYOCARDITIS." page 565; *
CIRCULATION RESEARCH, vol. 70, no. 4, 1992, pages 856 - 863 *
J.-L. VINCENT ET AL.: "ADMINISTRATION OF ANTI-TNF ANTIBODY IMPROVES LEFT VENTRICULAR FUNCTION IN SEPTIC SHOCK PATIENTS.", CHEST, vol. 101, no. 3, March 1992 (1992-03-01), CHICAGO, ILL. US, pages 810 - 815 *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2930185A1 (fr) 1996-02-09 2015-10-14 AbbVie Biotechnology Ltd Anticorps humains qui se lient au tnfalpha
EP2397494A1 (fr) 1996-02-09 2011-12-21 Abbott Biotechnology Ltd Anticorps humains qui se lient au TNFalpha
EP2357200A1 (fr) 1996-02-09 2011-08-17 Abbott Biotechnology Ltd Anticorps humains se fixant au facteur necrosant des tumeurs de type alpha
EP2930187A1 (fr) 1996-02-09 2015-10-14 AbbVie Biotechnology Ltd Anticorps humains qui se lient au tnf alpha humain
EP2305713A1 (fr) 1996-02-09 2011-04-06 Abbott Biotechnology Ltd Anticorps humains se fixant au facteur nécrosant des tumeurs de type alpha
EP2305712A1 (fr) 1996-02-09 2011-04-06 Abbott Biotechnology Ltd Anticorps humains se fixant au facteur necrosant des tumeurs de type alpha
EP2930186A1 (fr) 1996-02-09 2015-10-14 AbbVie Biotechnology Ltd Anticorps humains qui se lient au tnfalpha
EP2933267A1 (fr) 1996-02-09 2015-10-21 AbbVie Biotechnology Ltd Anticorps humains qui se lient au tnf alpha humain
EP2940044A1 (fr) 2001-06-08 2015-11-04 AbbVie Biotechnology Ltd Procédés d'administration d'anticorps anti-tnfalpha
EP2324851A1 (fr) 2001-06-08 2011-05-25 Abbott Biotechnology Ltd Methodes d'administration d'anticorps anti-TNFalpha
EP2364731A2 (fr) 2001-06-08 2011-09-14 Abbott Biotechnology Ltd Méthodes d'administration d'anticorps anti-TNFalpha
EP3190124A1 (fr) 2001-06-08 2017-07-12 AbbVie Biotechnology Ltd Adalimumab pour l'utilisation dans la thérapie de l'arthrite rhumatoïde
EP2359855A2 (fr) 2001-06-08 2011-08-24 Abbott Biotechnology Ltd Procédés d'administration d'anticorps anti-TNFalpha
EP2347766A1 (fr) 2002-04-26 2011-07-27 Abbott Biotechnology Ltd Utilisation d'anticorps anti-TNF dollar g(a) et d'un autre produit pharmaceutique
EP2196218A2 (fr) 2002-04-26 2010-06-16 Abbott Biotechnology Ltd Utilisation d'anticorps anti-TNFalpha et d'un autre médicament
EP2363145A1 (fr) 2002-08-16 2011-09-07 Abbott Biotechnology Ltd Formulation d'anticorps humains pour le traitement de troubles associés au tnf-alpha
US8940305B2 (en) 2002-08-16 2015-01-27 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
EP2363144A1 (fr) 2002-08-16 2011-09-07 Abbott Biotechnology Ltd Formulation d'anticorps humains pour le traitement de troubles associés au TNF-alpha
EP2361637A1 (fr) 2002-08-16 2011-08-31 Abbott Biotechnology Ltd Formulation d'anticorps humains pour le traitement de troubles associés au TNF-alpha
EP2359856A1 (fr) 2002-08-16 2011-08-24 Abbott Biotechnology Ltd Formulation d'anticorps humains pour le traitement de troubles associés au TNF-alpha
US9950066B2 (en) 2002-08-16 2018-04-24 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9750808B2 (en) 2002-08-16 2017-09-05 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-alpha associated disorders
US8911741B2 (en) 2002-08-16 2014-12-16 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-alpha associated disorders
US8916157B2 (en) 2002-08-16 2014-12-23 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US8916158B2 (en) 2002-08-16 2014-12-23 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US8932591B2 (en) 2002-08-16 2015-01-13 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US9302011B2 (en) 2002-08-16 2016-04-05 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-α associated disorders
US9738714B2 (en) 2002-08-16 2017-08-22 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9114166B2 (en) 2002-08-16 2015-08-25 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
WO2004016286A2 (fr) 2002-08-16 2004-02-26 Abbott Biotechnology Ltd. Formulation d'anti-corps humains pour le traitement de troubles lies au facteur de necrose tumorale alpha
US9732152B2 (en) 2002-08-16 2017-08-15 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9327032B2 (en) 2002-08-16 2016-05-03 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9295725B2 (en) 2002-08-16 2016-03-29 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9289497B2 (en) 2002-08-16 2016-03-22 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9220781B2 (en) 2002-08-16 2015-12-29 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9272041B2 (en) 2002-08-16 2016-03-01 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
US9272042B2 (en) 2002-08-16 2016-03-01 Abbvie Biotechnology Ltd Formulation of human antibodies for treating TNF-alpha associated disorders
EP2295071A1 (fr) 2002-10-24 2011-03-16 Abbott Biotechnology Ltd Thérapies faiblement dosées pour traiter des troubles pour lesquels l'activité des facteurs de nécrose tumorale alpha est préjudiciable
EP2332565A1 (fr) 2002-10-24 2011-06-15 Abbott Biotechnology Ltd. Thérapies faiblement dosées pour traiter des troubles pour lesquels l'activité des facteurs de nécrose tumorale alpha est préjudiciable
EP2338516A2 (fr) 2004-04-09 2011-06-29 Abbott Biotechnology Ltd Régimes posologiques multiples et variables pour traiter les troubles liés au TNF-alpha
EP2335732A2 (fr) 2004-04-09 2011-06-22 Abbott Biotechnology Ltd RÉGIME POSOLOGIQUE À VARIABLES MULTIPLES DESTINÉ A TRAITER DES MALADIES ASSOCIÉES À TNFalpha
EP2335731A2 (fr) 2004-04-09 2011-06-22 Abbott Biotechnology Ltd Régime posologique à variables multiples destiné à traiter des troubles associés à TNF-alpha
WO2005110452A2 (fr) 2004-04-09 2005-11-24 Abbott Biotechnology Ltd. Regime posologique a variables multiples destine a traiter des troubles associes a tnf?
EP2738178A1 (fr) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Purification d'anticorps
EP2738179A1 (fr) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Purification d'anticorps
EP3088410A2 (fr) 2006-04-05 2016-11-02 AbbVie Biotechnology Ltd Purification d'anticorps
US9505834B2 (en) 2011-04-27 2016-11-29 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9365645B1 (en) 2011-04-27 2016-06-14 Abbvie, Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9708400B2 (en) 2012-04-20 2017-07-18 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9683033B2 (en) 2012-04-20 2017-06-20 Abbvie, Inc. Cell culture methods to reduce acidic species
US9957318B2 (en) 2012-04-20 2018-05-01 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9708399B2 (en) 2013-03-14 2017-07-18 Abbvie, Inc. Protein purification using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9499616B2 (en) 2013-10-18 2016-11-22 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9522953B2 (en) 2013-10-18 2016-12-20 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9688752B2 (en) 2013-10-18 2017-06-27 Abbvie Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
WO2016160976A2 (fr) 2015-03-30 2016-10-06 Abbvie Inc. Protéines de liaison au tnf monovalentes
EP3078675A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
EP3078676A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
WO2016162537A1 (fr) 2015-04-10 2016-10-13 Ares Trading S.A Schéma posologique d'induction
WO2018124948A1 (fr) 2016-12-30 2018-07-05 Закрытое Акционерное Общество "Биокад" Composition pharmaceutique aqueuse d'un anticorps monoclonal recombinant pour le facteur de nécrose tumorale (tnf) α

Also Published As

Publication number Publication date
DE4307508A1 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
WO1994020139A1 (fr) Utilisation d'anticorps anti-tnf comme medicament therapeutique de l'insuffisance cardiaque (faiblesse du muscle cardiaque)
EP0804236B1 (fr) Utilisation d'anticorps anti-tnf dans la preparation de medicaments pour traiter des maladies a taux serique eleve d'interleukine-6
EP0453898B1 (fr) Utilisation d'anticorps contre le facteur de nécrose tumorale (TNF) comme médicament pour le traitement d'ischémies et de leurs conséquences
JPS58121213A (ja) アルツハイマ−病治療剤
DE112011102356T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit dem Herz-Kreislauf-System in Verbindung stehen
DE69024053T2 (de) Behandlung zur ermässigung von ödem und muskelschäden.
DE3390116C2 (de) Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel
DE19737348A1 (de) Neue pharmazeutische Zusammensetzung
DE69902127T2 (de) Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
DE19544768C1 (de) Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose
DE60125955T2 (de) Bioaktive fraktion von eurycoma longifolia
EP0331014A2 (fr) L'utilisation des inhibiteurs de l'enzyme de conversion pour la prophylaxie du diabète
DE69131517T2 (de) Verwendung von Prostaglandin-E1 zur Behandlung männlicher erektiler Impotenz
DE4127469A1 (de) Arzneimittel und ihre verwendung
WO1999021582A2 (fr) Utilisation d'antagonistes de tnf en tant que medicaments pour traiter les maladies septiques
DE3781045T2 (de) Antirheumatisches arzneimittel.
DE69937057T2 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
Iodice et al. Hemodynamic and ventilatory effects of intravenous salbutamol in patients affected by cold
DE3228007C2 (fr)
EP0820308B1 (fr) Conjugue pour le traitement de maladies inflammatoires
DE3925759A1 (de) Verwendung von ace-inhibitoren fuer die atheroskleroseprophylaxe
DE10247339A1 (de) Psoriasisbehandlung
DE4409513C1 (de) Verwendung von anti-TNF-Antikörpern als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
DE4308504A1 (de) Neue Verwendung einer Kombination aus Verapamil und Trandolapril
DE4122585C2 (de) Verwendung einer Peptidfraktion bei Stoffwechselstörungen mit Gewichtsverlust

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WA Withdrawal of international application
122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA